Study-related injury, costs, and insurance

Separate medical care from financial responsibility

Read the injury section as three questions: What care is available? Who may pay the medical bill? Is any additional compensation available for an injury? A statement that treatment is available answers the first question. It does not establish that the sponsor, research site, or insurer will pay the full cost.

When 21 CFR 50.25 (opens in a new tab) or 45 CFR 46.116 (opens in a new tab) applies, consent information for research involving more than minimal risk must explain whether compensation and medical treatments are available if injury occurs and, if so, what they consist of or where more information is available. FDA explains (opens in a new tab) that institutional policy, rather than FDA regulation, determines whether compensation or treatment will be offered and which conditions apply.

Keep participant payment separate from injury protection. Payment for visits, time, or inconvenience follows the study’s compensation schedule. Injury-related medical costs and any other injury compensation follow separate terms. Ask the site to explain each category.

Translate common injury language into unanswered questions

Language you may encounter	What it establishes	What to ask next
The study pays for research-required tests or procedures.	A defined set of protocol services has a payer.	Request the exact service list. Ask whether treatment for a complication falls outside it.
Routine care will be billed to insurance.	The site expects the health plan to process ordinary clinical services.	Confirm network status, prior authorization, cost sharing, exclusions, and the plan for a denial.
Medical treatment is available after a research injury.	The form identifies a route to care.	Ask who pays, which providers may be used, and whether emergency care follows different rules.
The sponsor has arranged payment for qualifying study-related medical costs.	A sponsor payment process exists.	Ask who determines relatedness, which expenses qualify, whether insurance is billed first, and which deadlines apply.
The participant or health plan is responsible for medical expenses.	The study makes no general promise to pay those expenses.	Ask about exceptions, institutional assistance, insurance coverage, and the review path.

Read the whole provision. A sentence about payment can depend on definitions, exclusions, notice requirements, or another policy referenced elsewhere. 45 CFR 46.116 (opens in a new tab) and 21 CFR 50.25 (opens in a new tab) prohibit consent language that makes participants waive legal rights or releases research parties from liability for negligence.

Build a service-by-service cost map

Classify each expected service instead of accepting a general statement that the study or insurance covers everything.

Research-required services: Identify study-only scans, laboratory tests, devices, procedures, and visits. Record whether the sponsor, site, participant, or insurer will be charged.
Routine patient care: Identify care you would receive outside the study. Confirm the billing provider, network status, authorization requirements, and expected cost sharing.
Injury or complication care: Record the initial care route, the party billed first, the sponsor or institutional review process, and exclusions.
Participation expenses: Track travel, lodging, meals, parking, childcare, time away from work, and companion costs separately. Confirm which expenses require advance approval.

Request the name of the office that prepared or reviewed the cost map. A study can involve separate hospital, physician, laboratory, pharmacy, imaging, and vendor billing systems. Ask whether each billing department has the study identifier and research-billing instructions.

Check the rule that applies to your health plan

For a qualified individual in an approved clinical trial involving cancer or another life-threatening disease or condition, federal law generally restricts non-grandfathered group and individual health plans from denying trial participation, denying or adding special limits to routine patient-cost coverage, or discriminating because of participation. Federal implementation guidance (opens in a new tab) describes the scope and boundaries. The rule excludes the investigational item itself, services used only for research data collection, and services clearly inconsistent with established standards of care. It does not create out-of-network benefits when the plan otherwise provides none.

Ask your plan whether the study and your circumstances meet the rule. Provide the trial identifier, protocol title, site, treating provider, and exact services. Confirm ordinary deductibles, copayments, coinsurance, network rules, and authorization steps. Request a written coverage or authorization decision when available.

Medicare uses a separate national coverage policy. CMS states (opens in a new tab) that Medicare covers routine costs in qualifying clinical trials and reasonable and necessary services used to diagnose or treat complications arising from participation, subject to other Medicare rules. The investigational item is generally excluded unless otherwise covered. Data-collection-only services and services customarily supplied free by the sponsor are also excluded from routine costs. Ask the study’s Medicare billing specialist to confirm trial qualification and the treatment-specific estimate.

Respond to an injury without losing the record

Use local emergency services for an emergency and follow the emergency instructions in the consent form. Do not wait for a sponsor or insurer to approve urgent care. After immediate care is addressed, contact the study’s clinical or after-hours number.

Tell an outside treating clinician that you are participating in research. Provide the study contact card or consent information when available. State the intervention or device you may have received without guessing a masked assignment. Ask the research team how emergency unblinding, product interruption, device handling, or follow-up should be managed.

Create a dated timeline. Record the onset, study activity that preceded it, people contacted, instructions received, care locations, tests, treatments, and follow-up. Ask the research team for a case or reference number and the correct contact for medical records and bills. Use a secure channel for health information.

Reconcile every explanation of benefits and bill

Keep the consent version, study identifier, contact list, visit records, discharge papers, itemized bills, explanations of benefits, claim numbers, denial notices, and written cost answers together. Label each charge as research-required, routine care, or possible injury-related care. Ask the site to correct the category when a service entered the wrong billing pathway.

An explanation of benefits is a coverage statement, not a bill. CMS advises (opens in a new tab) comparing its dates, services, allowed charges, insurer payment, patient balance, and remark codes with the provider’s bill. Contact the provider when the bill exceeds the patient balance shown by the plan or describes the wrong service.

Send only requested records through an approved secure method. Keep a copy and record the date, recipient, and response deadline.

Route each dispute to the office that can act

Clinical or safety question: contact the study clinician or after-hours number. Use emergency services when needed.
Research-cost allocation: contact the site’s research billing office and the sponsor injury-program contact named by the site.
Coverage or claim denial: contact the health plan and follow the appeal instructions and deadlines on its notice.
Consent, pressure, rights, or study-conduct concern: contact the participant-rights contact, reviewing IRB, or institutional human research protection office.
Possible regulatory noncompliance: identify which agency has jurisdiction. OHRP recommends (opens in a new tab) contacting the research team, reviewing IRB, and institutional human research protection office first for matters within its HHS-related jurisdiction. FDA publishes separate contacts (opens in a new tab) for complaints about FDA-regulated drug, biologic, and device trials.

This guide provides general U.S. educational information. It cannot interpret an insurance contract, determine liability, establish a legal deadline, or decide whether an event was caused by research. Sponsor terms, institutional policy, health-plan documents, federal program rules, state law, and the event facts may all matter. Consult a qualified insurance representative, patient advocate, or attorney for advice about your circumstances. Continue responding to bills, appeal notices, and legal documents while a research-cost review is pending.

Sources for this guide

Official guidance controls regulatory claims. Peer-reviewed research is identified when participant experience requires evidence beyond agency guidance. Links were checked September 5, 2026.

U.S. Food and Drug Administration. Informed Consent Guidance for IRBs, Clinical Investigators, and Sponsors (opens in a new tab).
U.S. Food and Drug Administration. Institutional Review Boards Frequently Asked Questions (opens in a new tab).
Electronic Code of Federal Regulations. 21 CFR 50.25 — Elements of informed consent (opens in a new tab).
Electronic Code of Federal Regulations. 45 CFR 46.116 — General requirements for informed consent (opens in a new tab).
Centers for Medicare & Medicaid Services. Affordable Care Act Implementation FAQs — Set 31 (opens in a new tab).
Centers for Medicare & Medicaid Services. National Coverage Determination 310.1 — Routine Costs in Clinical Trials (opens in a new tab).
Centers for Medicare & Medicaid Services. How to Read a Health Insurance Explanation of Benefits (opens in a new tab).
Office for Human Research Protections. Submitting a Complaint About Research Involving Humans (opens in a new tab).
U.S. Food and Drug Administration. Reporting Complaints Related to FDA-Regulated Clinical Trials (opens in a new tab).